BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 205 filers reported holding BRIDGEBIO PHARMA INC in Q1 2021. The put-call ratio across all filers is 1.92 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,123,629 | +42.8% | 80,532 | -6.8% | 0.07% | -23.7% |
| Q2 2023 | $1,486,906 | -4.8% | 86,448 | -8.2% | 0.10% | +54.0% |
| Q1 2023 | $1,561,803 | +128.8% | 94,198 | +5.1% | 0.06% | +57.5% |
| Q4 2022 | $682,737 | -18.8% | 89,598 | +5.9% | 0.04% | +8.1% |
| Q3 2022 | $841,000 | +9.5% | 84,598 | 0.0% | 0.04% | -35.1% |
| Q2 2022 | $768,000 | -17.9% | 84,598 | -8.2% | 0.06% | 0.0% |
| Q1 2022 | $936,000 | -58.3% | 92,198 | -31.5% | 0.06% | -51.3% |
| Q4 2021 | $2,243,000 | -77.8% | 134,498 | -75.5% | 0.12% | -85.3% |
| Q3 2021 | $10,093,000 | -21.9% | 548,184 | -5.7% | 0.80% | -47.6% |
| Q2 2021 | $12,919,000 | +6.8% | 581,178 | +12.7% | 1.52% | -72.9% |
| Q1 2021 | $12,098,000 | – | 515,769 | – | 5.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |